Cellceutix Corporation (OTC:CTIX) has reported a clinically meaningful improvement in four patients treated for inflammatory bowel problems with Brilacidin.
Six patients have been treated in the first cohort of the phase II study with the lowest dose, 50mg, and the results were from four of these patients.
Two achieved a 100% reduction in the symptoms and the other two 50%.
Brilacidin was generally well-tolerated and patients maintained stable normal vital signs during treatment, said Cellceut
In total, the phase II dosing study will comprise three cohorts (of six patients) suffering Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) who will receive progressively escalating doses.
Arthur Bertolino, the company’s chief medical officer, said: “These results are extremely encouraging.
“We anticipate the anti-inflammatory properties of Brilacidin alone will lead to multiple beneficial applications of the drug candidate beyond its already demonstrated effect in antibacterial indications.”.
Leo Ehrlich, chief executive, added: “We are delighted to see such promising responses to treatment in the first group of patients given the lowest dose of Brilacidin.
“The immunomodulatory and anti-inflammatory properties are at the core of effectively treating many diseases and conditions, such as IBDs and oral mucositis.”
Story by ProactiveInvestors